# Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection (Online Course: Apr 29, 2027) with Graeme Ladds

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/pharmacovigilance-an-overview-of-drug-safety-from-safety-collection-to-regulatory-inspecti/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Concise pharmacovigilance training covering EU requirements, company-wide staff duties, product safety and non-compliance risks*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6261350/pharmacovigilance-overview-drug-safety-safety?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=d7qkcn&amp;utm_campaign=2404189+-+Pharmacovigilance%3a+An+Overview+of+Drug+Safety+from+Safety+Collection+to+Regulatory+Inspection+(Online+Course%3a+Apr+29%2c+2027)+with+Graeme+Ladds&amp;utm_exec=jocamspi" rel="nofollow">"Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection (Apr 29, 2027)"</a> training has been added to **ResearchAndMarkets.com's** offering.  

Pharmacovigilance has undergone rapid regulatory change in recent years and become one of the most demanding aspects of the pharmaceutical industry to both understand and comply with. There are many requirements and duties for companies to perform regarding the safety of their products to satisfy regulatory demands, and sanctions for non-compliance can be severe.

EU pharmacovigilance legislation requires companies to train all staff, including those not working directly in pharmacovigilance, and this invaluable course will help you meet that requirement with a concise overview of the pharmacovigilance function and current regulatory requirements.

**CPD Hours:** 6

**Who Should Attend?**  

This course will be relevant for anyone requiring an overview of pharmacovigilance or wishing to consolidate existing knowledge. It will also benefit those working in pharmacovigilance, as well as those who support or interact with pharmacovigilance from areas including medical information, regulatory affairs, clinical, sales and marketing, legal, commercial and quality.

**Key Topics Covered:**

-   An introduction to EU pharmacovigilance
-   Documentation to be supplied to regulatory authorities
-   Department links in the company to pharmacovigilance
-   The roles and responsibilities of a licence holder
-   The role of the QPPV
-   SOPs in relation to pharmacovigilance
-   Pharmacovigilance inspections

**Speaker**

**Graeme Ladds**

Graeme Ladds, Director of PharSafer, has over 30 years' experience in the pharmaceutical industry. He began his career in 1989 at Ashbourne Pharmaceuticals as Head of Drug Safety & Medical Information, before going on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals.

He later founded his consultancy and specialist CRO, PharSafer Associates Ltd, where he has supported companies in establishing pharmacovigilance systems, conducting audits across Europe and the USA, developing SOPs, acting as a QP, and supporting regulatory inspections.

Since 1994, Graeme has also been involved in the monitoring of medical devices, including drug-device combinations, structural devices and electrical medical devices. His experience spans clinical trials and global device vigilance, alongside pharmacovigilance activities across both clinical development and post-marketing phases.

For more information about this training visit <a href="https://www.researchandmarkets.com/reports/6261350/pharmacovigilance-overview-drug-safety-safety?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=d7qkcn&amp;utm_campaign=2404189+-+Pharmacovigilance%3a+An+Overview+of+Drug+Safety+from+Safety+Collection+to+Regulatory+Inspection+(Online+Course%3a+Apr+29%2c+2027)+with+Graeme+Ladds&amp;utm_exec=jocamspi" rel="nofollow">https://www.researchandmarkets.com/r/qa1u14</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/ZWE2NTgxNmMtMGI3Ny00N2JlLWJjYmMtOTAzOWU1MDZiNDZjLTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Global Organ-on-Chip Market Size, Share, Trends and Forecast 2026-2036 | Set to Reach $2.5 Billion as Regulatory Acceptance and Animal Testing Alternatives Drive 22.2% CAGR](https://healthcarenews.io/news/global-organ-on-chip-market-size-share-trends-and-forecast-2026-2036-set-to-reach-2-5-bill.md)
- [Global Bariatric Surgery Devices Market Analysis and Forecast to 2036 | Expected to Reach US$3.42 Billion as Robotic, Endoscopic, and Revisional Procedures Drive Growth Amid GLP-1 Disruption](https://healthcarenews.io/news/global-bariatric-surgery-devices-market-analysis-and-forecast-to-2036-expected-to-reach-us.md)
- [Global Medical AI Apps Market Size and Forecast by Application, End Use and Region (2026-2033) | 19.1% CAGR Fueled by Digital Health and Personalized Care](https://healthcarenews.io/news/global-medical-ai-apps-market-size-and-forecast-by-application-end-use-and-region-2026-203.md)
- [Cell Line Development - Global Strategic Business Report 2026-2032: Capitalize on 10.1% CAGR](https://healthcarenews.io/news/cell-line-development-global-strategic-business-report-2026-2032-capitalize-on-10-1-cagr.md)
